Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-analysis of randomized trials

Archives of Internal Medicine

Volumn 167, Issue 2, 2007, Pages 117-124

  Dentali, Francesco ^a   Douketis, James D ^a,b   Lim, Wendy ^a   Crowther, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; MORTALITY; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBOEMBOLISM;

EID: 33846417966     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.2.117     Document Type: Review

References (54)

1. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):457S- 482S.
2. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case fatality rate, time course, anatomic sites and risk factors for bleeding. Arch Intern Med. 2006;166:853-859.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
4. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:429S-456S.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
6. Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol. 2003;42:2042-2048.
7. Younossi ZM, Strum WB, Schatz RA, Teirstein PS, Cloutier DA, Spinks TJ. Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci. 1997; 42:79-82.
8. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362-2367.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12.
10. Schulz KF. Assessing allocation concealment and blinding in randomized controlled trials: why bother? ACP J Club. 2000;132:A11-A12.
11. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
12. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG; Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3: measures of observer variability (kappa statistic). CMAJ. 2004;171:1369-1373.
13. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987; 126:161-169.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
18. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
19. Van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE; Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002; 360:109-113.
20. Perez-Gomez F, Alegria E, Berjon J, et al; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557-1566.
21. Rudnicka AR, Ashby D, Brennan P, Meade T. Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. Arch Intern Med. 2003;163:1454-1460.
22. Casais P, Meschengieser SS, Sanchez Luceros AG, Bermejo EI, Lazzari MA. Effect of low-dose aspirin on the international normalized ratio variability in patients with mechanical heart valve prostheses. Pathophysiol Haemost Thromb. 2002; 32:155-157.
23. Knottenbelt C, Brennan PJ, Meade TW. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med. 2002;162:881-886.
24. Huynh T, Theroux P, Bogaty P, et al. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103:3069-3074.
25. Lechat P, Lardoux H, Mallet A, et al. Anticoagulant (fluindione)-aspirin combination n patients with high-risk atrial fibrillation: a randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis. 2001; 12:245-252.
26. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000; 34:168-171.
27. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St Jude medical prosthesis. J Am Coll Cardiol. 2000;35:739-746.
28. Lechat P, Lardoux H, Mallet A, et al; Investigateurs de FFAACS. Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications: a randomized trial (FFAACS) [article in French]. Therapie. 2000;55:681-689.
29. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000; 31:828-833.
30. Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-840.
31. Gullov AL, Gade Koefoed B, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation. Arch Intern Med. 1999;159: 1322-1328.
32. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998; 351:233-241.
33. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
34. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J. 1998;32:233-237.
35. Fondevila CG, Meschengieser SS, Santareli MT, Aixala MT, Lazzari MA. Prevalence of anemia and occult blood losses in the long-term follow-up of cardiac mechanic valve patients treated with a combination of low-dose aspirin plus low-intensity acenocoumarin. Clin Appl Thromb Hemost. 1997;3:36-39.
36. Meschengieser SS, Fondevila CG, Frontroth J, Santareli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113: 910-916.
37. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? some preliminary findings. J Neurol Neurosurg Psychiatr. 1997;62:269-272.
38. Voith L, Pfliegler G, Hegedus I, et al. Coumarin combined with low-dose acetylsalicylic acid in the prevention of thromboembolic complications in patients with mitral and aortic valve prostheses [article in Hungarian]. Orv Hetil. 1997;138:925-929.
39. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
40. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
41. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524-529.
42. Cohen M, Adams PC, Bach M, et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the antithrombotic therapy in acute coronary syndromes study group). Am J Cardiol. 1990;66:1287-1292.
43. Dale J, Myhre E. Prevention of arterial embolism by acetylsalicyclic acid and anticoagulants in patients with heart valve prosthesis [article in Norwegian]. Tidsskr Nor Laegeforen. 1976;96: 1483-1485.
44. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol. 1983;51:1537-1541.
45. Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 1992; 68:1-6.
46. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J. 1980;99:746-752.
47. Dale J, Myhre E, Storstein O, et al. Prevention of arterial thromboembolism with acetylsalicylic acid. Am Heart J. 1977;94:101-111.
48. Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1976;72:127-129.
49. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: 494-502.
50. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143:1-13.
51. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a meta-analysis. Am Heart J. 1995; 130:547-552.
52. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol. 2001;37:569-578.
53. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282:2058-2067.
54. Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin? J Gen Intern Med. 2004;19:879-886.